We advised the placing agent in connection with the equity offering

Davis Polk advised the placing agent for the top-up placement of 28,000,000 new shares in Ocumension Therapeutics, for an aggregate consideration of approximately HK$793.8 million.

Davis Polk also advised the underwriters on Ocumension’s HK$1.55 billion IPO in July 2020.

Ocumension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies and has, in less than three years, built a strategically designed ophthalmic drug portfolio that is comprehensive, innovative and validated. To date, Ocumension had 16 drug assets in its portfolio, covering all major front- and back-of-the-eye diseases, making it one of only a few pharmaceutical companies in China with such full coverage.

The Davis Polk team included partners James C. Lin and Yang Chu, counsel Xuelin (Steve) Wang and associates Lillian Lian and Cathy Yuen. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post